Compare Oscar Health Inc (OSCR) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance

OSCR trades at $33.05, up 0.43% today, with strong technical momentum indicated by bullish moving averages. The company shows impressive growth with Q1 and Q2 2026 EPS beats and projected 2026 revenue of $15.3B. Valuation metrics appear reasonable with P/S of 0.63 and EV/EBITDA of 7.79, while profitability metrics show significant improvement from 2025 losses to projected 2026 net income of $551M.

The outlook remains positive with analyst consensus at $34.00 target and Strong Buy ratings from Zacks. Key opportunities include ACA market share gains and margin expansion, while risks center on rising medical costs and execution of growth targets. The stock faces near-term resistance at $34 with RSI suggesting potential overbought conditions.

Zimmer Biomet (ZBH) trades at $88.70, up 0.24% on the day, with a bearish technical outlook but strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $2.07 exceeding expectations. Revenue growth remains steady, reaching $8.23B in 2025, while profitability metrics like a 69.87% gross margin and 9.48% net margin reflect operational efficiency. Recent corporate news includes a $0.24 quarterly dividend declaration and leadership promotions aimed at accelerating commercial transformation.

The investment outlook is mixed, with analyst consensus leaning hold (52.38%) but a price target of $103.11 suggesting 16% upside. Key opportunities include sustained earnings beats and strategic initiatives, while risks involve rising debt levels, competitive pressures, and technical bearish signals. The stock's current valuation at a P/E of 21.57 appears reasonable relative to growth prospects, but investors should weigh fundamental strength against near-term technical weakness and macroeconomic headwinds in the healthcare sector.